A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)

Is this Study for You?

Let's Get Started!



Type of Study



Barbara Davis Center
University of Colorado Hospital

Principal Investigator
Photograph of Christopher Striebich,  MD, PhD

Christopher Striebich, MD, PhD

Study ID

Protocol Number: 22-0815

More information available at ClinicalTrials.gov: NCT04451772

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers